Financial report context:
part i item 1 . business . merck & co. , inc . ( 201cmerck 201d or the 201ccompany 201d ) is a global health care company that delivers innovative health solutions through its prescription medicines , vaccines , biologic therapies , animal health , and consumer care products , which it markets directly and through its joint ventures . the company 2019s operations are principally managed on a products basis and are comprised of four operating segments , which are the pharmaceutical , animal health , consumer care and alliances segments , and one reportable segment , which is the pharmaceutical segment . the pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures . human health pharmaceutical products consist of therapeutic and preventive agents , generally sold by prescription , for the treatment of human disorders . the company sells these human health pharmaceutical products primarily to drug wholesalers and retailers , hospitals , government agencies and managed health care providers such as health maintenance organizations , pharmacy benefit managers and other institutions . vaccine products consist of preventive pediatric , adolescent and adult vaccines , primarily administered at physician offices . the company sells these human health vaccines primarily to physicians , wholesalers , physician distributors and government entities . the company also has animal health operations that discover , develop , manufacture and market animal health products , including vaccines , which the company sells to veterinarians , distributors and animal producers . additionally , the company has consumer care operations that develop , manufacture and market over-the- counter , foot care and sun care products , which are sold through wholesale and retail drug , food chain and mass merchandiser outlets , as well as club stores and specialty channels . the company was incorporated in new jersey in for financial information and other information about the company 2019s segments , see item 7 . 201cmanagement 2019s discussion and analysis of financial condition and results of operations 201d and item 8 . 201cfinancial statements and supplementary data 201d below . all product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned , licensed to , promoted or distributed by merck , its subsidiaries or affiliates , except as noted . all other trademarks or services marks are those of their respective owners . product sales sales of the company 2019s top pharmaceutical products , as well as total sales of animal health and consumer care products , were as follows: .

Financial table:
( $ in millions ): total sales; 2013: $ 44033; 2012: $ 47267; 2011: $ 48047
( $ in millions ): pharmaceutical; 2013: 37437; 2012: 40601; 2011: 41289
( $ in millions ): januvia; 2013: 4004; 2012: 4086; 2011: 3324
( $ in millions ): zetia; 2013: 2658; 2012: 2567; 2011: 2428
( $ in millions ): remicade; 2013: 2271; 2012: 2076; 2011: 2667
( $ in millions ): gardasil; 2013: 1831; 2012: 1631; 2011: 1209
( $ in millions ): janumet; 2013: 1829; 2012: 1659; 2011: 1363
( $ in millions ): isentress; 2013: 1643; 2012: 1515; 2011: 1359
( $ in millions ): vytorin; 2013: 1643; 2012: 1747; 2011: 1882
( $ in millions ): nasonex; 2013: 1335; 2012: 1268; 2011: 1286
( $ in millions ): proquad/m-m-rii/varivax; 2013: 1306; 2012: 1273; 2011: 1202
( $ in millions ): singulair; 2013: 1196; 2012: 3853; 2011: 5479
( $ in millions ): animal health; 2013: 3362; 2012: 3399; 2011: 3253
( $ in millions ): consumer care; 2013: 1894; 2012: 1952; 2011: 1840
( $ in millions ): other revenues ( 1 ); 2013: 1340; 2012: 1315; 2011: 1665

Additional report context:
other revenues ( 1 ) 1340 1315 1665 ( 1 ) other revenues are primarily comprised of alliance revenue , miscellaneous corporate revenues and third-party manufacturing sales . on october 1 , 2013 , the company divested a substantial portion of its third-party manufacturing sales . table of contents .

Question: what is the growth rate in total sales in 2012?
Answer: -1.6%